Aratana Therapeutics, which is focused on the development and commercialization of prescription medication for pets, filed on Wednesday with the SEC to raise up to $58 million in an initial public offering. The Kansas City, KS-based company, which was founded in 2010 and has yet to generate any revenue, plans to list on the NASDAQ under the symbol PETX. Stifel and Lazard Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
